Royce & Associates LP Raises Stake in Standard BioTools Inc. (NASDAQ:LAB)

Royce & Associates LP increased its stake in shares of Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 136.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,455,503 shares of the company's stock after buying an additional 840,951 shares during the quarter. Royce & Associates LP owned about 0.39% of Standard BioTools worth $2,547,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its holdings in shares of Standard BioTools by 2.3% during the 3rd quarter. Geode Capital Management LLC now owns 6,949,717 shares of the company's stock worth $13,415,000 after buying an additional 154,848 shares during the last quarter. Hollow Brook Wealth Management LLC purchased a new position in Standard BioTools in the third quarter worth approximately $10,679,000. State Street Corp increased its stake in Standard BioTools by 26.7% during the third quarter. State Street Corp now owns 5,495,136 shares of the company's stock worth $10,606,000 after acquiring an additional 1,157,984 shares during the last quarter. Barclays PLC raised its position in Standard BioTools by 13.2% in the third quarter. Barclays PLC now owns 3,228,360 shares of the company's stock valued at $6,231,000 after purchasing an additional 377,195 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Standard BioTools by 188.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company's stock valued at $4,719,000 after purchasing an additional 1,597,728 shares during the last quarter. Hedge funds and other institutional investors own 53.74% of the company's stock.

Remove Ads

Standard BioTools Stock Up 0.9 %

NASDAQ LAB traded up $0.01 during trading on Tuesday, hitting $1.16. The stock had a trading volume of 1,120,328 shares, compared to its average volume of 2,367,188. The company has a market capitalization of $439.62 million, a PE ratio of -1.63 and a beta of 1.62. The firm has a 50 day moving average price of $1.38 and a 200 day moving average price of $1.70. Standard BioTools Inc. has a twelve month low of $0.99 and a twelve month high of $3.04.

Wall Street Analysts Forecast Growth

Separately, KeyCorp cut shares of Standard BioTools from an "overweight" rating to a "sector weight" rating in a research report on Thursday, February 27th.

Insider Activity

In related news, Director Casdin Partners Master Fund, L bought 4,820,959 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The stock was purchased at an average cost of $1.06 per share, for a total transaction of $5,110,216.54. Following the completion of the acquisition, the director now owns 58,846,780 shares in the company, valued at approximately $62,377,586.80. This trade represents a 8.92 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 53.10% of the company's stock.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.